Compare Abeona Therapeutics Inc (ABEO) vs Banco Bilbao Vizcaya Argentaria SA (BBVA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Banco Bilbao Vizcaya Argentaria SA — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Banco Bilbao Vizcaya Argentaria SA trades at $25.3 (market cap $143.90B). The key difference: Banco Bilbao Vizcaya Argentaria SA is far larger — about 385.5× Abeona Therapeutics Inc's market cap, and Banco Bilbao Vizcaya Argentaria SA pays a 4.13% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BBVA | |
|---|---|---|
Market Cap | $373.32M | $143.90B |
Sector | Health | Financials |
52-Week High | $7.23 | $26.14 |
52-Week Low | $4.17 | $14.73 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
BBVA trades at $26.07, up 1.84% today, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 26.51% net income margin and 18.67% ROE, while recent Q1 2026 earnings beat expectations. Positive sentiment is driven by analyst upgrades and news highlighting European bank outperformance and strategic partnerships, though regulatory scrutiny in Spain presents a headwind.
The outlook remains favorable given solid earnings growth, high ROE, and a majority analyst buy rating. Key risks include antitrust investigations and volatile cash flows, but the stock's reasonable P/E of 12.61 and dividend yield offer value. Upside is contingent on sustained loan growth and execution in key markets like Mexico.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Banco Bilbao Vizcaya Argentaria SA
Despite its Spanish origins, BBVA generates three quarters of its profits in emerging markets, especially Mexico that contributes nearly half of BBVA's net profit. BBVA is overwhelmingly a retail and commercial bank with corporate and investment banking forming a smaller part of the overall business.
Read more on BBVA →
